文献速递银屑病与炎症性皮肤病

每日一次罗氟司特泡沫0.3%治疗头皮及躯体银屑病的IIb期研究

Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
PubMed 文献 · Br J Dermatol · 2023-01-01

这项随机、双盲、赋形剂对照的IIb期研究纳入≥12岁头皮及躯体银屑病患者,按2:1随机接受罗氟司特泡沫0.3%或赋形剂治疗8周。第8周罗氟司特组S-IGA成功率达59.1%,显著高于赋形剂组的11.4%(P<0.001),且第2周即出现显著差异;安全性总体与赋形剂相似。

要点

  • 罗氟司特泡沫0.3%每日一次可显著改善头皮及躯体银屑病。
  • 第8周S-IGA成功率罗氟司特组59.1% vs 赋形剂组11.4%(P<0.001)。
  • 安全性总体与赋形剂相似,因不良事件停药者少。

核心结论

  • 结果支持进一步开发罗氟司特泡沫用于治疗头皮及躯体银屑病。

研究设计与样本

  • IIb期随机、双盲、赋形剂对照试验,纳入≥12岁头皮及躯体银屑病患者,按2:1随机接受罗氟司特泡沫0.3%或赋形剂治疗8周。

主要发现

  • 第8周S-IGA成功率达罗氟司特组59.1% vs 赋形剂组11.4%(P<0.001)。
  • 最早在第2周首次基线后访视时差异即有利于罗氟司特(P<0.001)。
  • 躯体IGA成功、头皮瘙痒数字评定量表及头皮银屑病严重程度指数等次要终点也见显著改善。
  • 罗氟司特安全性总体与赋形剂相似,治疗中出现的不良事件发生率低,因不良事件停药者少。
  • 研究纳入肤色深患者(11%)及青少年(0.7%)较少。

关键数值与推荐

  • 主要疗效终点为第8周头皮研究者整体评估(S-IGA)成功(评分为「清除」或「几乎清除」且较基线改善≥2级)。

临床怎么用

  • 每日一次罗氟司特泡沫0.3%可能用于改善头皮及躯体银屑病,但需进一步开发验证。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scalp psoriasis affects most patients with psoriasis, but it can be difficult to treat. OBJECTIVES: To evaluate the efficacy and safety of once-daily roflumilast foam 0.3% on scalp and body psoriasis. METHODS: In a phase IIb randomized controlled trial, adults and adolescents aged ≥ 12 years with scalp and body psoriasis were randomized (2 : 1) to roflumilast foam 0.3% or vehicle for 8 weeks. The primary efficacy endpoint was scalp Investigator Global Assessment (S-IGA) success (score of 'clear' or 'almost clear' plus ≥ 2-grade improvement from baseline) at week 8. Safety and tolerability were also evaluated. RESULTS: Significantly more roflumilast-treated patients (59.1%) than vehicle-treated patients (11.4%) achieved S-IGA success at week 8 (P < 0.001); differences favoured roflumilast as early as the first postbaseline visit at week 2 (P < 0.001). Significant improvements were also seen for secondary endpoints, including body IGA success, Scalp Itch Numeric Rating Scale and the Psoriasis Scalp Severity Index. The safety of roflumilast was generally similar to vehicle. Patients treated with roflumilast experienced low rates of treatment-emergent adverse events (AEs), with few discontinuations due to an AE. Few patients with skin of colour (11%) and few adolescents (0.7%) were included. CONCLUSIONS: The results support the further development of roflumilast foam for treating scalp and body psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kircik LH, Alonso-Llamazares J, Bhatia N, et al. Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study. Br J Dermatol. 2023. PMID: 37279795. doi:10.1093/bjd/ljad182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。